Face serums and creams: Clinical standard: 1-3% concentration Maximum typically used: 4% concentration Application: Once or twice daily Duration: Minimum 8-12 weeks for visible results Eye area products: Concentration: 1-2% (lower for sensitive periorbital skin) Application: Once daily, typically evening Amount: Pea-sized for both eyes Scalp solutions for hair: Concentration: 0.5% solution common Application: 1-2ml to affected areas once or twice daily Duration: 3-6 months minimum for meaningful changes Higher concentrations do not always mean better results with topicals
AOD-9604 is only the small C-terminal 176-191 fragment, so it lacks those receptor-binding regions and, in research models, does not reproduce growth hormone's growth-promoting or glucose-affecting actions it is studied specifically for the lipid-metabolism activity mapped to this fragment
AOD9604 is a synthetic peptide analog derived from the C-terminal region (176191) of human growth hormone (HGH), consisting of a defined amino acid sequence produced through controlled peptide synthesis
Patients taking tirzepatide alongside insulin or sulfonylureas face the highest risk, but even those on tirzepatide monotherapy should be cautious
Persistent nausea, reflux, constipation, rising resting heart rate, or broken sleep shows that the current dose has not settled
